The immune decision toward allograft tolerance in non-human primates requires early inhibition of innate immunity and induction of immune regulation

Transplant Immunology

Volumn 11, Issue 3-4, 2003, Pages 335-344

  Hutchings, Anne ^a   Wu, Jianguo ^a   Asiedu, Clement ^a   Hubbard, William ^a   Eckhoff, Devin ^a   Contreras, Juan ^a   Thomas, Francis T ^a   Neville, David ^b   Thomas, Judith M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Deoxyspergualin; Heat shock protein; Innate immunity; NF B; Primate; Tolerance

Indexed keywords

15 DEOXYSPERGUALIN; ACETYLSALICYLIC ACID; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOTOXIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; METHYLPREDNISOLONE; PROTEIN; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DECISION MAKING; DRUG DOSE REDUCTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOREGULATION; INCIDENCE; INHIBITION KINETICS; ISCHEMIA; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PERFUSION; LYMPH NODE BIOPSY; MACACA; MALE; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIMATE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECIPIENT; RHESUS MONKEY; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE;

EID: 0037850570     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(03)00054-6     Document Type: Article

References (45)

1. Thomas JM, Eckhoff DE, Contrereas JL, Lobashevsky AL, Hubbard WJ, Moore JK, et al. Durable donor-specific T and B cell tolerance in rhesus macaques-induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: Absence of chronic allograft nephropathy. Transplantation 2000;69(12):2497-2503.
2. Thomas JM, Hubbard WJ, Sooudi SK, Thomas FT. STEALTH matters: A novel paradigm of durable primate allograft tolerance. Immunol Rev 2001;183:223-233.
3. Hutchings A, Hubbard WJ, Thomas FT, Thomas JM. STEALTH in transplantation tolerance. Immunol Res 2002;26(1-3):143-152.
4. Wu L, D'Amico A, Winkel KD, Suter M, Lo D, Shortman K. RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity 1998;9(6):839-847.
5. Contreras JL, Wang PX, Eckhoff DE, Lobashevsky AL, Asiedu C, Frenette L, et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: A matter of proinflammatory cytokine control. Transplantation 1998;65(9):1159-1169.
6. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18(49):6853-6866.
7. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000;12(11):1539-1546.
8. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13(1):114-119.
9. Dong C, Flavell RA. Th1 and Th2 cells. Curr Opin Hematol 2001;8:47-51.
10. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749-795.
11. Moore KW, De Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
12. Bellinghausen I, Brand U, Steinbrink K, Enk AH, Knop J, Saloga J. Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: Differences from hydrocortisone-treated dendritic cells. J Allergy Clin Immunol 2001;108(2):242-249.
13. Neville DM Jr, Scharff J, Hu HZ, Rigaut K, Shiloach J, Slingerland W, et al. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. J Immunother Emphasis Tumor Immunol 1996;19(2):85-92.
14. Lobashevsky A, Smith JP, Kasten-Jolly J, Horton H, Knapp L, Bontrop RE, et al. Identification of DRB alleles in rhesus monkeys using polymerase chain reaction-sequence-specific primers (PCR-SSP) amplification. Tissue Antigens 1999;54(3):254-263.
15. Lobashevsky AL, Thomas JM. Six mamu-A locus alleles defined by a polymerase chain reaction sequence-specific primer method. Hum Immunol 2000;61(10):1013-1020.
16. Thomas JM, Carver M, Scott J, Williams E, Thomas F. Effect of rabbit anti-human thymocyte globulin on lymphocyte sub-populations and functions following allotransplantation in the rhesus monkey. Transplantation 1979;27(3):163-170.
17. Thomas JM, Carver M, Cunningham P, Park K, Gonder J, Thomas F. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism. Transplantation 1987;43(3):332-338.
18. Thomas JM, Neville DM. Contreras JL, Eckhoff DE, Meng G, Lobashevsky AL, et al. Preclinical studies of allograft tolerance in rhesus monkeys: A novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997;64(1):124-135.
19. Thomas JM, Contreras JL, Smyth CA, Lobashevsky A, Jenkins S, Hubbard WJ, et al. Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of type 1 diabetes. Diabetes 2001;50(6):1227-1236.
20. Maeda K, Umeda Y, Saino T. Synthesis and background chemistry of 15-deoxyspergualin. Ann NY Acad Sci 1993;685:123-135.
21. Asiedu C, Pereboev A, Curiel DT, Dong SS, Hutchings A, Thomas JM. Converting non-human primate dendritic cells into potent antigen-specific cellular immunosuppressants by genetic modification. Immunol Res 2002;26(1-3):297-302.
22. Thomas F, Wu J, Contreras JL, Smyth C, Bilbao G, He J, et al. A tripartite anoikis-like mechanism causes early isolated islet apoptosis. Surgery 2001;130(2):333-338.
23. Thomas JM, Contreras JL, Jiang XL, Eckhoff DE, Wang PX, Hubbard WJ, et al. Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999;68(11):1660-1673.
24. Thomas JM, Jenkins S, Contreras J, Eckhoff D, Hubbard WJ, Thomas FT, et al. Does a type 2-biased relative cytokine ratio (RCR) during recovery from T cell depletion forecast permanent tolerance in primates? Am J Transplant 2002;2(Suppl. 3):144.
25. Hubbard WJ, Moore JK, Contreras JL, Smyth CA, Chen ZW, Lobashevsky AL, et al. Phenotypic and functional analysis of T-cell recovery after anti-CD3 immunotoxin treatment for tolerance induction in rhesus macaques. Hum Immunol 2001;62(5):479-487.
26. Nadler SG, Eversole AC, Tepper MA, Cleaveland JS. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 1995;17(6):700-703.
27. Nadler SG, Dischino DD, Malacko AR, Cleaveland JS, Fujihara SM, Marquardt H. Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Biochem Biophys Res Commun 1998;253(1):176-180.
28. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995;155(1):489-498.
29. Konieczny BT, Dai Z, Elwood ET, Saleem S, Linsley PS, Baddoura FK, et al. IFN-gamma is critical for long-term allograft survival-induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 1998;160(5):2059-2064.
30. Kishimoto K, Dong VM, Issazadeh S, Fedoseyeva EV, Waaga AM, Yamada A, et al. The role of CD154-CD40 vs. CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin Invest 2000;106(1):63-72.
31. Davies JD, Martin G, Phillips J, Marshall SE, Cobbold SP, Waldmann H. T cell regulation in adult transplantation tolerance. J Immunol 1996;157(2):529-533.
32. Waaga AM, Gasser M, Kist-Van Holthe JE, Najafian N, Muller A, Vella JP, et al. Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest 2001;107(7):909-916.
33. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001;166(6):3789-3796.
34. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: New therapeutics for graft-vs.-host disease. J Exp Med 2002;196(3):401-406.
35. Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H. Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol 2002;168(11):5558-5565.
36. Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994;179(2):493-502.
37. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, De Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389(6652):737-742.
38. Land W. The potential impact of the reperfusion injury on acute and chronic rejection events following organ transplantation. Transplant Proc 1994;26(6):3169-3171.
39. Land W, Schneeberger H, Schleibner S, Illner WD, Abendroth D, Rutili G, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994;57(2):211-217.
40. Daemen MA, De Vries B, Buurman WA. Apoptosis and inflammation in renal reperfusion injury. Transplantation 2002;73(11):1693-1700.
41. Land W. Postischemic reperfusion injury to allografts - A case for 'innate immunity'? Eur Surg Res 2002;34(1-2):160-169.
42. Hoffmann SC, Kampen RL, Amur S, Sharaf MA, Kleiner DE, Hunter K, et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation 2002;74(7):916-923.
43. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, et al. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6(4):435-442.
44. Galluci S, Lolkema M, Matzinger P. Natural adjuvants: Endogenous activators of dendritic cells. Nat Med 1999;5(11):1249-1255.
45. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994;12:991-1045.